Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has engaged Digital Offering LLC as its exclusive placement agent to evaluate potential strategic capital raising options.
The engagement supports Liminatus's exploration of a digital asset treasury strategy and may include various financing structures such as convertible debentures, equity-linked securities, or alternative instruments. Digital Offering will help source institutional and digital asset-focused investors while ensuring regulatory compliance.
CEO Chris Kim emphasized that while no financing transaction has been finalized, this partnership allows the company to explore both traditional and digital asset funding opportunities strategically.
Liminatus Pharma (NASDAQ: LIMN), un'azienda biofarmaceutica in fase preclinica specializzata in immunoterapie oncologiche, ha incaricato Digital Offering LLC come agente esclusivo per valutare potenziali opzioni strategiche di raccolta di capitale.
Questo incarico supporta l'esplorazione da parte di Liminatus di una strategia di tesoreria basata su asset digitali e può includere diverse strutture di finanziamento come debentures convertibili, titoli collegati a equity o strumenti alternativi. Digital Offering aiuterà a individuare investitori istituzionali e focalizzati sugli asset digitali, garantendo al contempo la conformità normativa.
Il CEO Chris Kim ha sottolineato che, anche se non è stata ancora finalizzata alcuna operazione di finanziamento, questa collaborazione consente all'azienda di esplorare in modo strategico sia opportunità di finanziamento tradizionali sia basate su asset digitali.
Liminatus Pharma (NASDAQ: LIMN), una empresa biofarmacéutica en etapa preclínica centrada en inmunoterapias contra el cáncer, ha contratado a Digital Offering LLC como su agente exclusivo para evaluar posibles opciones estratégicas de recaudación de capital.
Este compromiso apoya la exploración de Liminatus de una estrategia de tesorería con activos digitales y puede incluir diversas estructuras de financiamiento como bonos convertibles, valores vinculados a acciones o instrumentos alternativos. Digital Offering ayudará a buscar inversores institucionales y enfocados en activos digitales, asegurando el cumplimiento normativo.
El CEO Chris Kim enfatizó que, aunque no se ha concretado ninguna transacción de financiamiento, esta asociación permite a la empresa explorar de forma estratégica oportunidades de financiamiento tanto tradicionales como basadas en activos digitales.
Liminatus Pharma (NASDAQ: LIMN)는 암 면역치료제에 중점을 둔 전임상 단계의 바이오제약 회사로, 전략적 자본 조달 옵션을 평가하기 위해 Digital Offering LLC를 독점 배치 에이전트로 선정했습니다.
이번 계약은 Liminatus가 디지털 자산 재무 전략을 모색하는 데 도움을 주며, 전환사채, 주식 연계 증권 또는 대체 금융 수단과 같은 다양한 금융 구조를 포함할 수 있습니다. Digital Offering은 제도권 및 디지털 자산 중심 투자자를 발굴하고 규제 준수를 보장할 예정입니다.
CEO 크리스 김은 아직 자금 조달 거래가 확정된 것은 아니지만, 이번 파트너십을 통해 회사가 전통적 및 디지털 자산 기반 자금 조달 기회를 전략적으로 탐색할 수 있다고 강조했습니다.
Liminatus Pharma (NASDAQ : LIMN), une société biopharmaceutique en phase préclinique spécialisée dans les immunothérapies contre le cancer, a engagé Digital Offering LLC en tant qu'agent exclusif pour évaluer des options stratégiques potentielles de levée de capitaux.
Cette collaboration soutient l'exploration par Liminatus d'une stratégie de trésorerie basée sur les actifs numériques et peut inclure diverses structures de financement telles que les obligations convertibles, les titres liés aux actions ou d'autres instruments alternatifs. Digital Offering aidera à identifier des investisseurs institutionnels et spécialisés dans les actifs numériques tout en garantissant la conformité réglementaire.
Le PDG Chris Kim a souligné que, bien qu'aucune transaction de financement n'ait encore été finalisée, ce partenariat permet à l'entreprise d'explorer stratégiquement des opportunités de financement traditionnelles et basées sur les actifs numériques.
Liminatus Pharma (NASDAQ: LIMN), ein biopharmazeutisches Unternehmen in der präklinischen Phase mit Fokus auf Krebsimmuntherapien, hat Digital Offering LLC als exklusiven Vermittler beauftragt, um potenzielle strategische Kapitalbeschaffungsoptionen zu prüfen.
Dieser Auftrag unterstützt Liminatus bei der Erkundung einer Digital-Asset-Treasury-Strategie und kann verschiedene Finanzierungsstrukturen wie wandlungsfähige Schuldverschreibungen, aktiengebundene Wertpapiere oder alternative Instrumente umfassen. Digital Offering wird institutionelle und auf digitale Vermögenswerte fokussierte Investoren akquirieren und dabei die Einhaltung regulatorischer Vorgaben sicherstellen.
CEO Chris Kim betonte, dass zwar noch keine Finanzierungsvereinbarung abgeschlossen wurde, diese Partnerschaft dem Unternehmen jedoch ermöglicht, sowohl traditionelle als auch digitale Finanzierungsoptionen strategisch zu prüfen.
- Partnership with SEC- and FINRA-registered broker-dealer adds credibility to funding initiatives
- Proactive approach to exploring innovative financing options including digital assets
- Potential to strengthen capital structure through diverse funding sources
- No guarantee of successful financing transaction
- Potential future dilution depending on chosen financing structure
- Early-stage company with no approved products seeking additional funding
Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing paths
LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into an engagement agreement with Digital Offering LLC, a FINRA- and SEC-registered broker-dealer, to serve as its exclusive placement agent in connection with the company’s evaluation of a potential strategic capital raise.
This engagement supports Liminatus’s previously disclosed review of a digital asset treasury strategy, as the company evaluates modern financial tools to strengthen its capital structure. The funding initiative may involve various exempt financing structures, including—but not limited to—convertible debentures, equity-linked securities, or other alternative instruments that comply with applicable U.S. securities laws.
Under this engagement agreement, Digital Offering is engaged to assist the company in sourcing institutional and digital asset–focused investors and structuring a compliant financing solution.
“At Liminatus, our core mission is advancing transformative immunotherapies for cancer,” said Chris Kim, CEO of Liminatus. “As we work toward that goal, we are also taking proactive steps to strengthen our capital strategy. Partnering with Digital Offering allows us to explore strategic funding opportunities—both in traditional markets and the evolving digital asset landscape—with discipline and foresight.”
Liminatus emphasizes that the engagement of Digital Offering relates strictly to placement agent services. No financing transaction has been finalized, and there is no assurance that one will occur. Any potential capital transaction resulting from this engagement would remain subject to the Board of Directors' approval and full regulatory compliance.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Liminatus Pharma, Inc.
Liminatus is a preclinical-stage biopharmaceutical company developing immunotherapies for patients with cancer. The Company is advancing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune responses. Liminatus is also committed to responsible innovation in capital strategy to support its long-term scientific and operational objectives.
Forward-Looking Statements
Certain statements in this press release constitute forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects. Future developments affecting Liminatus may not be those that Liminatus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of Liminatus), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Liminatus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
In addition, statements that “we believe” and similar statements reflect beliefs and opinions on the relevant subject. These statements are based upon information available to Liminatus as of the date of this press release, and while Liminatus believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that Liminatus has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements as predictions of future results. Liminatus’s actual future results may be materially different from what it expects. Liminatus qualifies all forward-looking statements by these cautionary statements.
Investor Relations Contact: Company Contact: Liminatus Pharma, Inc. info@liminatuspharma.com
FAQ
What is the purpose of Liminatus Pharma's (LIMN) engagement with Digital Offering LLC?
What types of financing structures is Liminatus Pharma (LIMN) considering?
Has Liminatus Pharma (LIMN) finalized any financing transaction?
What is Liminatus Pharma's (LIMN) main business focus?
Who will Digital Offering LLC target as potential investors for Liminatus (LIMN)?
